```
REGISTERED COMPANY NUMBER: 06996068 (England and Wales)
REGISTERED CHARITY NUMBER: 1132984
```
## **`REPORT OF THE TRUSTEES AND`**
```
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31ST AUGUST 2025
```
## **`FOR`**
## **`THE INTERNATIONAL CML FOUNDATION`**
```
Gibbons Mannington & Phipps LLP
Chartered Accountants
20 Eversley Road
Bexhill-on-Sea
East Sussex
TN40 1HE
```
```
THE INTERNATIONAL CML FOUNDATION
```
## **`CONTENTS OF THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST AUGUST 2025`**
**----- Start of picture text -----**
Page
Report of the Trustees 1 to 4
Independent Examiner's Report 5
Statement of Financial Activities 6
Balance Sheet 7
Notes to the Financial Statements 8 to 15
Detailed Statement of Financial Activities 16
**----- End of picture text -----**
```
THE INTERNATIONAL CML FOUNDATION (REGISTERED NUMBER: 06996068)
```
## **`REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31ST AUGUST 2025`**
```
ThetrusteeswhoarealsodirectorsofthecharityforthepurposesoftheCompaniesAct2006,present their
reportwiththefinancialstatementsofthecharityfortheyearended31stAugust2025.Thetrustees have
adoptedtheprovisionsofAccountingandReportingbyCharities:StatementofRecommended Practice
applicabletocharitiespreparingtheiraccountsinaccordancewiththeFinancialReporting Standard
applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).
```
## **`OBJECTIVES AND ACTIVITIES`**
## **`Objectives and aims`**
```
TheobjectoftheFoundationistheadvancementofhealthbytheimprovementofthetreatmentinall parts
oftheworldofchronicmyeloidleukaemiaandrelateddiseases(together"CML")andforthepurpose of
carrying out those general objects, the primary objects of the Foundation are in particular:-
```
```
(i) to improve clinical practice and disease monitoring in the treatment of CML
```
```
(ii) to support, encourage and promote research into the causes, prevention, study and treatment of CML
```
```
(iii)topromoteandsupporttheeducationofanddisseminateknowledgeamongstclinicians, scientists,
health professionals and patients in matters concerning CML
```
```
(iv)topromote,fosterandco-ordinatecollaborationthatisparticularly(butnotexclusively) international
andisnotonlyintheareasandactivitiesofclinicalpracticediseasemonitoringandresearchintoCML but
alsoinanyareaoractivitywhichisormaybeconducivetotheaccelerationofthecontroland/orcure of
CML
```
```
(v)topromote,setup,establishandsupportandshareandexchangeknowledgewithother organisations
whose objects are similar to these general or primary objects
```
```
(vi)toassistorpromoteanyothercharitablepurposeswhicharerelatedtothesegeneraland primary
objects.
```
## **`Significant activities`**
```
In furtherance of the objects, the Foundation has the following powers:-
```
```
(i) to promote or carry out research
```
```
(ii) to provide advice
```
```
(iii) to give and exchange information and advice and promote learning, study and research
```
```
(iv)tocommission,publish,distributeandcontributetopapers,books,periodicals,reports,leaflets, posters
and other publications of any description
```
```
(v) to hold, attend and sponsor conferences, meetings, lectures, exhibitions and discussions
```
```
(vi) to raise funds and to apply for and solicit grants from pharmaceutical companies anywhere in the world.
```
## **`Public benefit`**
```
TheTrusteeshaveconsideredtheirdutytohavedueregardtopublicbenefitguidancepublishedby the
Commissionandintheiropinion,theforegoingreportontheachievementsandperformance demonstrates
that they have complied therewith.
```
```
Page 1
```
```
THE INTERNATIONAL CML FOUNDATION (REGISTERED NUMBER: 06996068)
```
## **`REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31ST AUGUST 2025`**
## **`ACHIEVEMENTS AND PERFORMANCE`**
## **`Charitable activities`**
```
TheInternationalCMLFoundation(iCMLf)isaglobalcharityworkingtoimprovetheoutcomesfor people
withchronicmyeloidleukemia(CML),particularlyinlow-andmiddle-incomecountries(LMICs).Our mission
istofosterglobalcollaboration,sharebestpractices,buildclinicalcapacity,andaccelerateresearch to
ultimately find a cure for CML.
```
```
In2024-2025,theiCMLfcontinuedtoaddressunmetneedsinCMLcareandeducationbydriving global
research, enhancing medical education, and fostering access to expert guidance and clinical excellence.
```
## **`SUMMARY OF CORE PROGRAMS AND IMPACT`**
## **`1. Global Research`**
```
TheiCMLfleadsinternationalcollaborationsthatinvestigatecriticalquestionstoimproveCML treatment,
```
```
including:
```
```
-BigDataProjects:ThroughtheGenomicsAllianceandTFR(Treatment-FreeRemission)Alliance, the
Foundationisworkingtoanalyseover3,400datasetsfrom27sitesacross19countries.Theseprojects aim
to understand genomic drivers of CML and improve the success rates of therapy discontinuation strategies.
-ResearchPublications:Threesignificantpeer-reviewedstudieswerepublishedthisyear,providing new
insights into CML biolog y and management.
```
## **`2. Education and Clinical Capacity Building`**
```
PhysicianeducationonclinicalmanagementanddiagnosticsremainsacorefocusfortheiCMLf. Programs
include:
```
```
-KnowledgeCentre:Over1,200professionalsaccessedexpert-lededucationalmodules,includinga new
focus on fertility and pregnancy in CML.
```
```
-RegionalDiscussionGroups:Ninesessionsheldacrossthreecontinentsengaged250physicians from
44 countries, promoting region-specific dialogue and clinical learning.
```
```
-ClinicalConversationsandForums:Thesesessionsfacilitatedglobalpeerlearning.Over 2,000
```
```
on-demand views were recorded across three key sessions.
```
```
-PublicationsandCasediscussions:Morethan8,000viewsofchallengingcasediscussions, including
complexcasesonpediatricrelapse,pregnancy,andfourth-linetherapies,providedpracticalguidance for
clinicians.
```
```
-In-PersonEvents:iCMLfconvenedexpertpanelsatmajorglobaleventssuchastheJohn Goldman
Conference, the Ame rican Society of Hematology meeting, and the Indian Cancer Congress.
```
## **`3. Awareness, Recognition, and Advocacy`**
```
-iCMLfPrizes:Prestigiousawardswerepresentedtoleadersinresearch,clinicalpractice,and patient
advocacy.
```
```
-PatientSupport:ProgramsandcommunityengagementssuchasFriendsofMaxinIndia amplified
patient voices and needs.
```
## **`FINANCIAL REVIEW`**
## **`Financial position`**
```
The financial position of the International CML Foundation remains solid.
```
## **`Expenditure`**
```
-Totalexpenditureonprograms:67%onphysicianeducation,11%ondiseaseresearch,and9%on patient
support.
```
```
- 36% of all expenditures directly supported people with CML in LMICs.
```
```
- 13% was allocated to fundraising and 10% to governance.
```
## **`Principal funding sources`**
```
TheiCMLfworkscloselywithindustryandcommunitypartnerstosecureunrestrictedgrantsand sponsorship
for our programs and activities. The iCMLf requests donations through the iCMLf website.
```
## **`Reserves policy`**
```
Thereservesattheyearendwere£184,718(2024-£263,528).ItisthepolicyoftheTrusteesto maintain
sufficientreservestoensurethedaytodayrunningoftheFoundation.Thelevelofreservesand current
financialcommitmentsarereviewedregularlyatTrustees'meetings.TheFoundationplanstohold a
minimumof£150,000asreservefunding.Thisistheamountforthefoundationtooperatewithout further
income/outgoings for one year.
```
```
Page 2
```
```
THE INTERNATIONAL CML FOUNDATION (REGISTERED NUMBER: 06996068)
```
## **`REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31ST AUGUST 2025`**
## **`FUTURE PLANS`**
```
TheTrusteesareproudoftheiCMLf'sachievementsin2024-2025.OurcommitmenttoequityinCML care,
globalcollaboration,andscientificinnovationcontinuestodrivetangibleimprovementsinpatient outcomes.
Lookingahead,theiCMLfwillbuildonthemomentumofitscurrentprogramsbyexpandingits research
networks,launchingnewregionallyfocusededucationinitiatives,anddeepeningengagementwith patient
communities.TheFoundationremainsfocusedonsupportingcliniciansandresearchersworldwideas we
work toward a cure for CML.
```
## **`STRUCTURE, GOVERNANCE AND MANAGEMENT`**
## **`Governing document`**
```
Thecharityiscontrolledbyitsgoverningdocument,adeedoftrust,andconstitutesalimited company,
limited by guarantee, as defined by the Companies Act 2006.
```
## **`Recruitment and appointment of new trustees`**
```
ThepowerofappointingneworadditionalTrusteesisvestedintheexistingTrustees.Priorto appointment,
new Trustees would be introduced to the workings of the Foundation and advised of their responsibilities.
```
```
TheiCMLfBoardofDirectorsiscomposedofgloballyrenownedhematologistsandresearcherswho provide
strategicleadershiptotheFoundation.Toensurediverseperspectives,theBoardincludes representatives
fromlow-andmiddle-incomecountries,notablyBrazilandIndia.In2024,theiCMLfestablisheda Patient
AdvisoryCommitteetostrengthenpatientrepresentationwithinitswork.Thisnewcommittee brings
togethereightCMLpatientsandadvocatesfromfivecountries,whowillcollaboratewiththe Scientific
AdvisoryCommitteetohelpshapeandsupporttheFoundation'smission.TheiCMLf'soperations are
managedbyamultidisciplinaryteambasedacrossAustralia,theUnitedKingdom,Germany,the United
States, and India.
```
## **`Organisational structure`**
```
TheChiefExecutivereportstotheeleveniCMLfDirectors,specificallytheiCMLfChairman.The iCMLf
Directors are supported by an Executive Committee of 3 directors and the Chief Executive.
```
```
Theoperationalteam;CommunicationsDirector,CommunicationsManager,DigitalMediaOfficer, and
ProgramManager,reporttotheChiefExecutive.InJune2024aDevelopmentManagerwashiredtojoin the
operational team.
```
```
Strategicdirection,financialreviewandbudgetapprovalaresetatanannualiCMLfDirectorsmeeting in
September/October each year. Further planning and discussion meetings are held quarterly.
```
```
Strategicplanningisassistedwithanannualadvisor'smeeting.ThisincludestheScientific Advisory
Committee and Patient Advisory Committee.The Patient Advisors also meet quarterly.
```
```
Theoperationalteammeetsquarterly.TheCommunicationsDirector/CommunicationsManager meet
biweeklywiththeChiefExecutiverespectively.TheProgramManagerandDevelopmentManager meet
weeklywiththeChiefExecutiveforbusinessplanning.TheChiefExecutiveandiCMLfChairman meet
monthly.
```
```
DecisionsareescalatedfromtheoperationalteamtotheChiefExecutive,iCMLfChairman,iCMLf Executive
Committee and iCMLf Board of Directors according to scale and impact.
```
## **`REFERENCE AND ADMINISTRATIVE DETAILS Registered Company number`**
```
06996068 (England and Wales)
```
## **`Registered Charity number`**
```
1132984
```
## **`Registered office`**
```
20 Eversley Road
Bexhill-on-Sea
East Sussex
TN40 1HE
```
```
Page 3
```
```
THE INTERNATIONAL CML FOUNDATION (REGISTERED NUMBER: 06996068)
```
## **`REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31ST AUGUST 2025`**
```
Trustees
Professor T P Hughes
Professor J Cortes Professor
Professor B Druker Professor
Professor A Hochhaus Professor
Professor J Radich Professor
Professor C Schiffer Professor
Professor J F Apperley DM FRCP/Path Professor
Professor M Mauro Professor
Professor G Saglio Professor
Dr K B B Pagnano Medical doctor
Dr H Malhotra Medical doctor
```
## **`Company Secretary`**
```
Ms N C Evans
```
## **`Independent Examiner`**
```
R Appleyard FCA
Gibbons Mannington & Phipps LLP
Chartered Accountants
20 Eversley Road
Bexhill-on-Sea
East Sussex
TN40 1HE
```
## **`Bankers`**
```
HSBC Bank, 152 Portobello Road, London, W11 2EA
```
## **`QUALIFYING THIRD PARTY INDEMNITY PROVISION`**
```
Thereisaqualifyingthirdpartyindemnityinforceatthedateofapprovalofthisreport,forthebenefit of
every director or other officer or auditor.
```
```
ThisreporthasbeenpreparedinaccordancewiththespecialprovisionsofPart15oftheCompanies Act
2006 relating to small companies.
```
```
Approved by order of the board of trustees on 3rd July 2026 and signed on its behalf by:
```
```
Professor J Cortes - Trustee
```
```
Page 4
```
```
INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF
THE INTERNATIONAL CML FOUNDATION (REGISTERED NUMBER: 06996068)
```
```
Independentexaminer'sreporttothetrusteesofTheInternationalCMLFoundation ('the
```
## **`Company')`**
```
IreporttothecharitytrusteesonmyexaminationoftheaccountsoftheCompanyfortheyear ended
31st August 2025.
```
## **`Responsibilities and basis of report`**
```
Asthecharity'strusteesoftheCompany(andalsoitsdirectorsforthepurposesofcompanylaw)you are
responsibleforthepreparationoftheaccountsinaccordancewiththerequirementsoftheCompanies Act
2006 ('the 2006 Act').
```
```
HavingsatisfiedmyselfthattheaccountsoftheCompanyarenotrequiredtobeauditedunderPart16 of
the2006Actandareeligibleforindependentexamination,Ireportinrespectofmyexaminationof your
charity'saccountsascarriedoutunderSection145oftheCharitiesAct2011('the2011Act').In carrying
outmyexaminationIhavefollowedtheDirectionsgivenbytheCharityCommissionunderSection 145(5)
(b) of the 2011 Act.
```
## **`Independent examiner's statement`**
```
Sinceyourcharity'sgrossincomeexceeded£250,000yourexaminermustbeamemberofalistedbody. I
canconfirmthatIamqualifiedtoundertaketheexaminationbecauseIamamemberoftheInstitute of
Chartered Accountants in England and Wales, which is one of the listed bodies.
```
```
Ihavecompletedmyexamination.Iconfirmthatnomattershavecometomyattentioninconnection with
the examination giving me cause to believe:
```
`1. accounting records were not kept in respect of the Company as required by Section 386 of the 2006 Act; or`
`2. the accounts do not accord with those records; or`
`3. the accounts do not comply with the accounting requirements of Section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or`
`4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).`
```
Ihavenoconcernsandhavecomeacrossnoothermattersinconnectionwiththeexaminationto which
attentionshouldbedrawninthisreportinordertoenableaproperunderstandingoftheaccountsto be
reached.
```
```
R Appleyard FCA
The Institute of Chartered Accountants in England and Wales
```
```
Gibbons Mannington & Phipps LLP
Chartered Accountants
20 Eversley Road
Bexhill-on-Sea
East Sussex
TN40 1HE
```
```
13th July 2026
```
```
Page 5
```
```
THE INTERNATIONAL CML FOUNDATION
```
## **`STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31ST AUGUST 2025`**
|`Unrestricted`
`funds`
`Notes`
`£`
**`INCOME AND ENDOWMENTS FROM`**
`Donations and legacies`
**`106,197`**
`Other income`
`2`
**`(6,233)`**
**`Total`**
**`99,964`**
**`EXPENDITURE ON`**
**`Charitable activities`**
`Preceptorships`
**`-`**
`Diagnostics program`
**`-`**
`Scientific meetings`
**`-`**
`Clinical and Scientific communication`
**`-`**
`Fundraising`
**`38,313`**
`Cure Consortium`
**`-`**
`Covid-19 & CML Study`
**`-`**
`Knowledge Centre`
**`-`**
`Clinical Conversations program`
**`-`**
`RDG`
**`-`**
`Alliances`
**`-`**
`Education meetings`
**`-`**
`Physian support, education and best practice`
`sharing`
**`63,084`**
`Scientific research`
**`7,290`**
`Patient and carer support and education`
**`2,515`**
`Admin / Governance`
**`17,357`**
`Other`
**`(1,980)`**
**`Total`**
**`126,579`**
**`NET INCOME/(EXPENDITURE)`**
**`(26,615)`**
**`RECONCILIATION OF FUNDS`**
`Total funds brought forward`
**`30,933`**
**`TOTAL FUNDS CARRIED FORWARD`**
**`4,318`**|`Restricted`
`funds`
`£`
**`161,210`**
**`-`**
**`161,210`**
**`-`**
**`-`**
**`-`**
**`-`**
**`-`**
**`-`**
**`-`**
**`-`**
**`-`**
**`-`**
**`-`**
**`-`**
**`129,061`**
**`54,218`**
**`30,126`**
**`-`**
**`-`**
**`213,405`**
**`(52,195)`**
**`232,595`**
**`180,400`**|**`2025`**
**`Total`**
**`funds`**
**`£`**
**`267,407`**
**`(6,233)`**
**`261,174`**
**`-`**
**`-`**
**`-`**
**`-`**
**`38,313`**
**`-`**
**`-`**
**`-`**
**`-`**
**`-`**
**`-`**
**`-`**
**`192,145`**
**`61,508`**
**`32,641`**
**`17,357`**
**`(1,980)`**
**`339,984`**
**`(78,810)`**
**`263,528`**
**`184,718`**|_`2024`_
_`Total`_
_`funds`_
_`£`_
_`319,194`_
_`(8,700)`_
_`310,494`_
_`3,808`_
_`11,841`_
_`31,833`_
_`66,157`_
_`25,784`_
_`1,820`_
_`1,750`_
_`3,675`_
_`11,585`_
_`32,709`_
_`11,103`_
_`21,959`_
_`-`_
_`-`_
_`-`_
_`-`_
_`14,998`_
_`239,022`_
_`71,472`_
_`192,056`_
_`263,528`_|
|---|---|---|---|
```
The notes form part of these financial statements
```
```
Page 6
```
```
THE INTERNATIONAL CML FOUNDATION (REGISTERED NUMBER: 06996068)
```
## **`BALANCE SHEET`**
## **`31ST AUGUST 2025`**
|`Unrestricted`
`funds`
`Notes`
`£`
**`CURRENT ASSETS`**
`Debtors`
`9`
**`9,118`**
`Cash at bank and in hand`
**`-`**
**`9,118`**
**`CREDITORS`**
`Amounts falling due within one year`
`10`
**`(4,800)`**
**`NET CURRENT ASSETS`**
**`4,318`**
**`TOTAL ASSETS LESS CURRENT`**
**`LIABILITIES`**
**`4,318`**
**`NET ASSETS`**
**`4,318`**
**`FUNDS`**
`11`
`Unrestricted funds`
`Restricted funds`
**`TOTAL FUNDS`**|`Restricted`
`funds`
`£`
**`101,223`**
**`79,177`**
**`180,400`**
**`-`**
**`180,400`**
**`180,400`**
**`180,400`**|**`2025`**
**`Total`**
**`funds`**
**`£`**
**`110,341`**
**`79,177`**
**`189,518`**
**`(4,800)`**
**`184,718`**
**`184,718`**
**`184,718`**
**`4,318`**
**`180,400`**
**`184,718`**|_`2024`_
_`Total`_
_`funds`_
_`£`_
_`51,632`_
_`218,676`_
_`270,308`_
_`(6,780)`_
_`263,528`_
_`263,528`_
_`263,528`_
`30,933`
`232,595`
`263,528`|
|---|---|---|---|
```
ThecharitablecompanyisentitledtoexemptionfromauditunderSection477oftheCompaniesAct 2006
for the year ended 31st August 2025.
```
```
Themembershavenotrequiredthecompanytoobtainanauditofitsfinancialstatementsforthe year
ended 31st August 2025 in accordance with Section 476 of the Companies Act 2006.
```
```
The trustees acknowledge their responsibilities for
```
- `(a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and`
- `(b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.`
```
Thesefinancialstatementshavebeenpreparedinaccordancewiththeprovisionsapplicableto charitable
companies subject to the small companies regime.
```
```
ThefinancialstatementswereapprovedbytheBoardofTrusteesandauthorisedforissueon3rdJuly 2026
and were signed on its behalf by:
```
```
J Cortes - Trustee
```
```
The notes form part of these financial statements
```
```
Page 7
```
```
THE INTERNATIONAL CML FOUNDATION
```
## **`NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST AUGUST 2025`**
## **`1. ACCOUNTING POLICIES`**
## **`Basis of preparing the financial statements`**
```
Thefinancialstatementsofthecharitablecompany,whichisapublicbenefitentityunderFRS 102,
havebeenpreparedinaccordancewiththeCharitiesSORP(FRS102)'AccountingandReporting by
Charities:StatementofRecommendedPracticeapplicabletocharitiespreparingtheiraccounts in
accordancewiththeFinancialReportingStandardapplicableintheUKandRepublicofIreland (FRS
102)(effective1January2019)',FinancialReportingStandard102'TheFinancialReporting Standard
applicableintheUKandRepublicofIreland'andtheCompaniesAct2006.Thefinancial statements
have been prepared under the historical cost convention.
```
## **`Income`**
```
Items of income are recognised and included in the accounts when all of the following criteria
are met:
```
- `The charity or its subsidiary have entitlement to the funds;`
- `any performance conditions attached to the item(s) of income have been met or are fully within the control of the charity or its subsidiary;`
- `there is sufficient certainty that receipt of the income is considered probable; and`
- `the amount can be measured reliably.`
## **`Expenditure`**
```
Liabilitiesarerecognisedasexpenditureassoonasthereisalegalorconstructive obligation
committingthecharitytothatexpenditure,itisprobablethatatransferofeconomicbenefitswill be
requiredinsettlementandtheamountoftheobligationcanbemeasuredreliably.Expenditure is
accountedforonanaccrualsbasisandhasbeenclassifiedunderheadingsthataggregateall cost
relatedtothecategory.Wherecostscannotbedirectlyattributedtoparticularheadingsthey have
been allocated to activities on a basis consistent with the use of resources.
```
## **`Debtors`**
```
Debtorsarerecognisedatthesettlementamountdueafteranytradediscountoffered. Prepayments
are valued at the amount prepaid after taking account of any trade discounts due.
```
## **`Creditors and provisions`**
```
Creditorsandprovisionsarerecognisedwherethecharityhasapresentobligationresultingfrom a
pasteventthatwillprobablyresultinthetransferoffundstoathirdpartyandtheamountdue to
settletheobligationcanbemeasuredorestimatedreliably.Creditorsandprovisionsare normally
recognised at their settlement amount after allowing for any trade discounts due.
```
## **`Taxation`**
```
The charity is exempt from corporation tax on its charitable activities.
```
## **`Fund accounting`**
```
Unrestrictedfundscanbeusedinaccordancewiththecharitableobjectivesatthediscretionof the
trustees.
```
```
Restrictedfundscanonlybeusedforparticularrestrictedpurposeswithintheobjectsofthe charity.
Restrictionsarisewhenspecifiedbythedonororwhenfundsareraisedforparticular restricted
purposes.
```
```
Furtherexplanationofthenatureandpurposeofeachfundisincludedinthenotestothe financial
statements.
```
## **`Foreign currencies`**
```
Assetsandliabilitiesinforeigncurrenciesaretranslatedintosterlingattheratesofexchange ruling
atthebalancesheetdate.Transactionsinforeigncurrenciesaretranslatedintosterlingattherate of
exchangerulingatthedateoftransaction.Exchangedifferencesaretakenintoaccountinarriving at
the operating result and are shown as other income.
```
```
continued...
```
```
Page 8
```
```
THE INTERNATIONAL CML FOUNDATION
```
## **`NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31ST AUGUST 2025`**
## **`2. OTHER INCOME`**
```
Otherincomeconsistsoftheprofit/lossonforeigncurrencyexchangeinaccordancewith the
accounting policy on foreign exchange transactions.
```
## **`3. SUPPORT COSTS`**
|`Management`
`fees`
`Finance`
`Other`
`£`
`£`
`£`
`Other resources`
`expended`
**`-`**
**`-`**
**`-`**
`Fundraising`
**`31,203`**
**`-`**
**`1,877`**
`Physian support,`
`education and best`
`practice sharing`
**`116,842`**
**`50`**
**`-`**
`Scientific research`
**`23,474`**
**`-`**
**`-`**
`Patient and carer support`
`and education`
**`14,088`**
**`-`**
**`-`**
`Admin / Governance`
**`9,789`**
**`490`**
**`144`**
**`195,396`**
**`540`**
**`2,021`**
`Support costs, included in the above, are as follows:`
**`Management fees`**
`Fundraising`
`£`
`Management & admin`
**`31,203`**
`Patient`
`and carer`
`support`
`and`
`Admin /`
`education`
`Governance`
`£`
`£`
`Management & admin`
**`14,088`**
**`9,789`**
**`Finance`**
`Physian`
`support,`
`education`
`and best`
`practice`
`Admin /`
`sharing`
`Governance`
`£`
`£`
`Bank charges`
**`50`**
**`490`**|`Governance`
`costs`
`£`
**`(1,980)`**
**`-`**
**`-`**
**`-`**
**`-`**
**`6,540`**
**`4,560`**
`Physian`
`support,`
`education`
`and best`
`practice`
`sharing`
`£`
**`116,842`**
**`2025`**
`Total`
`activities`
**`£`**
**`195,396`**
**`2025`**
`Total`
`activities`
**`£`**
**`540`**|`Totals`
`£`
**`(1,980)`**
**`33,080`**
**`116,892`**
**`23,474`**
**`14,088`**
**`16,963`**
**`202,517`**
`Scientific`
`research`
`£`
**`23,474`**
_`2024`_
`Total`
`activities`
_`£`_
**_`192,302`_**
_`2024`_
`Total`
`activities`
_`£`_
**_`545`_**|
|---|---|---|
||||
```
continued...
```
```
Page 9
```
```
THE INTERNATIONAL CML FOUNDATION
```
## **`NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31ST AUGUST 2025`**
## **`3. SUPPORT COSTS - continued Other`**
|**`SUPPORT COSTS - continued`**
**`Other`**|||||
|---|---|---|---|---|
||||**`2025`**|_`2024`_|
|||`Admin /`|`Total`|`Total`|
||`Fundraising`|`Governance`|`activities`|`activities`|
||`£`|`£`|**`£`**|_`£`_|
|`Sundry office costs`|**`1,877`**|**`144`**|**`2,021`**|**_`3,273`_**|
|**`Governance costs`**|||||
||||**`2025`**|_`2024`_|
||`Other`||||
||`resources`|`Admin /`|`Total`|`Total`|
||`expended`|`Governance`|`activities`|`activities`|
||`£`|`£`|**`£`**|_`£`_|
|`Accountancy - Independent`|||||
|`examination fee`|**`(1,980)`**|**`6,540`**|**`4,560`**|**_`4,596`_**|
## **`4. NET INCOME/(EXPENDITURE)`**
```
Net income/(expenditure) is stated after charging/(crediting):
```
|||**`2025`**|_`2024`_|
|---|---|---|---|
|||**`£`**|_`£`_|
|`Accountancy - Independent`|`examination fee`|**`4,560`**|_`4,596`_|
## **`5. TRUSTEES' REMUNERATION AND BENEFITS`**
```
Therewerenotrustees'remunerationorotherbenefitsfortheyearended31stAugust2025nor for
the year ended 31st August 2024.
```
## **`Trustees' expenses`**
```
Therewerenotrustees'expensespaidfortheyearended31stAugust2025norfortheyear ended
31st August 2024.
```
## **`6. STAFF COSTS`**
```
The average monthly number of employees during the year was as follows:
```
|`Charitable activities`
`The number of employees whose employee benefits (excluding employer `
`£60,000 was:`
`£80,001 - £90,000`|**`2025`**
_`2024`_
**`6`**
_`6`_
`pension costs) exceeded`
**`2025`**
_`2024`_
**`1`**
_`1`_|
|---|---|
```
continued...
```
```
Page 10
```
```
THE INTERNATIONAL CML FOUNDATION
```
## **`NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31ST AUGUST 2025`**
## **`7. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES`**
|`Unrestricted`
`funds`
`£`
**`INCOME AND ENDOWMENTS FROM`**
`Donations and legacies`
`104,927`
`Other income`
`(8,700)`
**`Total`**
`96,227`
**`EXPENDITURE ON`**
**`Charitable activities`**
`Preceptorships`
`3,808`
`Diagnostics program`
`-`
`Scientific meetings`
`31,833`
`Clinical and Scientific communication`
`35,060`
`Fundraising`
`25,784`
`Cure Consortium`
`-`
`Covid-19 & CML Study`
`1,750`
`Knowledge Centre`
`3,675`
`Clinical Conversations program`
`11,585`
`RDG`
`17,160`
`Alliances`
`-`
`Education meetings`
`1,554`
`Other`
`14,998`
**`Total`**
`147,207`
**`NET INCOME/(EXPENDITURE)`**
`(50,980)`
**`RECONCILIATION OF FUNDS`**
`Total funds brought forward`
`81,912`
**`TOTAL FUNDS CARRIED FORWARD`**
`30,932`|`Restricted`
`funds`
`£`
`214,267`
`-`
`214,267`
`-`
`11,841`
`-`
`31,097`
`-`
`1,820`
`-`
`-`
`-`
`15,549`
`11,103`
`20,405`
`-`
`91,815`
`122,452`
`110,144`
`232,596`|`Total`
`funds`
`£`
`319,194`
`(8,700)`
`310,494`
`3,808`
`11,841`
`31,833`
`66,157`
`25,784`
`1,820`
`1,750`
`3,675`
`11,585`
`32,709`
`11,103`
`21,959`
`14,998`
`239,022`
`71,472`
`192,056`
`263,528`|
|---|---|---|
## **`8. VOLUNTEERS`**
```
Thecharityheavilyreliesuponthemanymedicalprofessionalswhodonatetheirtimetohelprun the
variouscharitableactivitiesundertaken.Itisnotpossibletoaccuratelycalculatethevalueof the
servicescontributedbythesevolunteersandthereforethenumbersdonotreflecteitherthe income
or expenditure, however it is thought to be in the region of £230,000.
```
```
continued...
```
```
Page 11
```
```
THE INTERNATIONAL CML FOUNDATION
```
## **`NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31ST AUGUST 2025`**
## **`9. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR`**
||**`2025`**|_`2024`_|
|---|---|---|
||**`£`**|_`£`_|
|`Other debtors`|**`21,209`**|_`51,632`_|
|`Prepayments and accrued income`|**`89,132`**|_`-`_|
||**`110,341`**|_`51,632`_|
```
Includedwithinotherdebtorsisabalanceof£757(2024-£49,997)inrespectoffundsheld by
Paypal.
```
## **`10. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR`**
|`Accrued expenses`
**`MOVEMENT IN FUNDS`**
`At 1/9/24`
`£`
**`Unrestricted funds`**
`General fund`
**`30,933`**
**`Restricted funds`**
`Novartis Pharmaceuticals Corporation`
**`91,250`**
`Novartis - Knowledge`
**`-`**
`Incyte - Alliance/Cure Programs`
**`111,218`**
`Patient Education`
**`30,127`**
`Novartis Chile`
**`-`**
`Novartis Saudi`
**`-`**
**`232,595`**
**`TOTAL FUNDS`**
**`263,528`**
`Net movement in funds, included in the above are as follows:`
`Incoming`
`resources`
`£`
**`Unrestricted funds`**
`General fund`
**`99,964`**
**`Restricted funds`**
`Novartis Pharmaceuticals Corporation`
**`-`**
`Novartis - Knowledge`
**`72,077`**
`Incyte - Alliance/Cure Programs`
**`1`**
`Patient Education`
**`-`**
`Novartis Chile`
**`9,235`**
`Novartis Saudi`
**`79,897`**
**`161,210`**
**`TOTAL FUNDS`**
**`261,174`**|**`2025`**
**`£`**
**`4,800`**
`Net`
`movement`
`in funds`
`£`
**`(26,615)`**
**`(42,029)`**
**`760`**
**`(54,217)`**
**`(30,127)`**
**`1,063`**
**`72,355`**
**`(52,195)`**
**`(78,810)`**
`Resources`
`expended`
`£`
**`(126,579)`**
**`(42,029)`**
**`(71,317)`**
**`(54,218)`**
**`(30,127)`**
**`(8,172)`**
**`(7,542)`**
**`(213,405)`**
**`(339,984)`**|_`2024`_
_`£`_
_`6,780`_
`At`
`31/8/25`
`£`
**`4,318`**
**`49,221`**
**`760`**
**`57,001`**
**`-`**
**`1,063`**
**`72,355`**
**`180,400`**
**`184,718`**
`Movement`
`in funds`
`£`
**`(26,615)`**
**`(42,029)`**
**`760`**
**`(54,217)`**
**`(30,127)`**
**`1,063`**
**`72,355`**
**`(52,195)`**
**`(78,810)`**|
|---|---|---|
## **`11. MOVEMENT IN FUNDS`**
```
continued...
```
```
Page 12
```
```
THE INTERNATIONAL CML FOUNDATION
```
```
NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31ST AUGUST 2025
```
## **`11. MOVEMENT IN FUNDS - continued`**
## **`Comparatives for movement in funds`**
|**`Unrestricted funds`**
`General fund`
**`Restricted funds`**
`Novartis Pharmaceuticals Corporation`
`Pfizer Grant`
`Incyte - Alliance/Cure Programs`
`Patient Education`
**`TOTAL FUNDS`**
`Comparative net movement in funds, included in the above ar`
**`Unrestricted funds`**
`General fund`
**`Restricted funds`**
`Novartis Pharmaceuticals Corporation`
`Takeda Oncology`
`Pfizer Grant`
`Incyte - Alliance/Cure Programs`
`Patient Education`
`Novartis RDG`
**`TOTAL FUNDS`**|`At 1/9/23`
`£`
`81,912`
`103,090`
`7,054`
`-`
`-`
`110,144`
`192,056`
`e as follows:`
`Incoming`
`resources`
`£`
`96,227`
`1`
`31,097`
`-`
`117,088`
`50,532`
`15,549`
`214,267`
`310,494`|`Net`
`movement`
`in funds`
`£`
`(50,979)`
`(11,840)`
`(7,054)`
`111,218`
`30,127`
`122,451`
`71,472`
`Resources`
`expended`
`£`
`(147,206)`
`(11,841)`
`(31,097)`
`(7,054)`
`(5,870)`
`(20,405)`
`(15,549)`
`(91,816)`
`(239,022)`|`At`
`31/8/24`
`£`
`30,933`
`91,250`
`-`
`111,218`
`30,127`
`232,595`
`263,528`
`Movement`
`in funds`
`£`
`(50,979)`
`(11,840)`
`-`
`(7,054)`
`111,218`
`30,127`
`-`
`122,451`
`71,472`|
|---|---|---|---|
```
continued...
```
```
Page 13
```
```
THE INTERNATIONAL CML FOUNDATION
```
```
NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31ST AUGUST 2025
```
## **`11. MOVEMENT IN FUNDS - continued`**
```
A current year 12 months and prior year 12 months combined position is as follows:
```
|**`Unrestricted funds`**
`General fund`
**`Restricted funds`**
`Novartis Pharmaceuticals Corporation`
`Pfizer Grant`
`Novartis - Knowledge`
`Incyte - Alliance/Cure Programs`
`Novartis Chile`
`Novartis Saudi`
**`TOTAL FUNDS`**|`At 1/9/23`
`£`
`81,912`
`103,090`
`7,054`
`-`
`-`
`-`
`-`
`110,144`
`192,056`|`Net`
`movement`
`in funds`
`£`
`(77,594)`
`(53,869)`
`(7,054)`
`760`
`57,001`
`1,063`
`72,355`
`70,256`
`(7,338)`|`At`
`31/8/25`
`£`
`4,318`
`49,221`
`-`
`760`
`57,001`
`1,063`
`72,355`|
|---|---|---|---|
||||`180,400`|
||||`184,718`|
```
Acurrentyear12monthsandprioryear12monthscombinednetmovementinfunds,includedin the
above are as follows:
```
|**`Unrestricted funds`**
`General fund`
**`Restricted funds`**
`Novartis Pharmaceuticals Corporation`
`Takeda Oncology`
`Pfizer Grant`
`Novartis - Knowledge`
`Incyte - Alliance/Cure Programs`
`Patient Education`
`Novartis RDG`
`Novartis Chile`
`Novartis Saudi`
**`TOTAL FUNDS`**|`Incoming`
`resources`
`£`
`196,191`
`1`
`31,097`
`-`
`72,077`
`117,089`
`50,532`
`15,549`
`9,235`
`79,897`
`375,477`
`571,668`|`Resources`
`expended`
`£`
`(273,785)`
`(53,870)`
`(31,097)`
`(7,054)`
`(71,317)`
`(60,088)`
`(50,532)`
`(15,549)`
`(8,172)`
`(7,542)`
`(305,221)`
`(579,006)`|`Movement`
`in funds`
`£`
`(77,594)`
`(53,869)`
`-`
`(7,054)`
`760`
`57,001`
`-`
`-`
`1,063`
`72,355`
`70,256`
`(7,338)`|
|---|---|---|---|
```
continued...
```
```
Page 14
```
```
THE INTERNATIONAL CML FOUNDATION
```
## **`NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31ST AUGUST 2025`**
## **`12. RELATED PARTY DISCLOSURES`**
```
There were no related party transactions for the year ended 31st August 2025.
```
```
Page 15
```
```
THE INTERNATIONAL CML FOUNDATION
```
## **`DETAILED STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31ST AUGUST 2025`**
||`2025`|_`2024`_|
|---|---|---|
||`£`|_`£`_|
|**`INCOME AND ENDOWMENTS`**|||
|**`Donations and legacies`**|||
|`Donations`|**`267,407`**|_`319,194`_|
|**`Other income`**|||
|`Exchange rate differences`|**`(6,233)`**|_`(8,700)`_|
|**`Total incoming resources`**|**`261,174`**|_`310,494`_|
|**`EXPENDITURE`**|||
|**`Charitable activities`**|||
|`Honoraria`|**`46,424`**|_`-`_|
|`Preceptorship Program`|**`49`**|_`3,791`_|
|`Edu meetings`|**`21,572`**|_`21,959`_|
|`Conversations`|**`2,149`**|_`-`_|
|`Scientific meetings`|**`1,190`**|_`1,567`_|
|`Knowledge Centres`|**`4,298`**|_`-`_|
|`Communications`|**`16,409`**|_`7,379`_|
|`Management and general expenses`|**`513`**|_`-`_|
|`Diagnosis & testing`|**`4,298`**|_`-`_|
|`ICMLF forum`|**`-`**|_`32`_|
|`Research`|**`30,177`**|_`-`_|
|`Fundraising`|**`3,520`**|_`2,011`_|
|`Translator fees`|**`6,868`**|_`1,567`_|
||**`137,467`**|_`38,306`_|
|**`Support costs`**|||
|**`Management fees`**|||
|`Management & admin`|**`195,396`**|_`192,302`_|
|**`Finance`**|||
|`Bank charges`|**`540`**|_`545`_|
|**`Other`**|||
|`Sundry office costs`|**`2,021`**|_`3,273`_|
|**`Governance costs`**|||
|`Accountancy - Independent examination`|||
|`fee`|**`4,560`**|_`4,596`_|
|`Total resources expended`|**`339,984`**|_`239,022`_|
|**`Net (expenditure)/income`**|**`(78,810)`**|_`71,472`_|
```
This page does not form part of the statutory financial statements
```
```
Page 16
```